Clinical Trials
64 trialsNCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT03406299 2026-04-09
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05254847 2026-01-20
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Fudan University
Phase 2 Completed
NCT03044587 2025-10-01
NIFE
AIO-Studien-gGmbH
Phase 2 Completed
NCT04466891 2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04907851 2025-03-17
KEYNOTE-E86
Redx Pharma Ltd
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT04677504 2024-07-03
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT04720131 2024-01-30
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Phase 2 Completed
NCT03230318 2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2 Completed
NCT03796429 2023-11-29
A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT03260712 2023-11-03
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03833661 2023-10-25
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Phase 2 Completed
NCT04722133 2023-10-11
Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy
Yonsei University
Phase 2 Completed
NCT02866383 2023-09-22
CheckPAC
Herlev Hospital
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT05190575 2023-07-27
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03079427 2022-12-06
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
Asan Medical Center
Phase 2 Completed
NCT03101566 2022-10-28
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03524508 2022-08-24
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Asan Medical Center
Phase 2 Completed
NCT03110328 2022-06-15
Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Samsung Medical Center
Phase 2 Completed
NCT02703714 2022-01-25
Pembrolizumab and GM-CSF in Biliary Cancer
University of California, San Francisco
Phase 2 Completed
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03486678 2021-10-28
SHR-1210 in Combination With GEMOX in Patients With Advanced BTC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT04656249 2021-06-04
LENABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT04642664 2021-06-03
ACABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT03778593 2021-02-04
FOLFIRINOX for 2nd-line Treatment of BTC
Dong-A University Hospital
Phase 2 Completed
NCT03830606 2021-02-01
The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma
ChineseAMS
Phase 2 Completed
NCT03613168 2021-01-05
BILHER
Asan Medical Center
Phase 2 Completed
NCT02579616 2020-12-23
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT03231176 2020-11-19
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
Phase 2 Completed
NCT00948935 2020-03-11
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02966821 2019-02-27
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
Hutchmed
Phase 2 Completed
NCT01917617 2019-02-21
Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
Phase 2 Completed
NCT02053376 2019-01-30
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
University of Pittsburgh
Phase 2 Completed
NCT02433639 2018-09-10
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Completed
NCT01815307 2018-05-16
Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
Phase 2 Completed
NCT00142480 2018-04-25
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02558959 2018-02-13
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Zhejiang University
Phase 2 Completed
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed
NCT02346032 2017-04-26
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Samsung Medical Center
Phase 2 Completed
NCT00361231 2017-02-07
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT01572324 2017-01-04
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
Phase 2 Completed